Interventions to reduce mortality in sub-Saharan Africa among HIV-infected adults not yet on antiretroviral therapy

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 1, 2012, Pages 43-50

  Peterson, Kevin ^a   Van Griensven, Johan ^a   Huis In 'T Veld, Diana ^b   Colebunders, Robert ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

adherence; antiretroviral therapy; clinical staging; counseling; HIV; HIV testing; lost to follow up; mortality; opportunistic infection; sub Saharan Africa

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; ISONIAZID;

AFRICA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTACT EXAMINATION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DISEASE SURVEILLANCE; EARLY INTERVENTION; FOLLOW UP; HEALTH CARE PLANNING; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERDISCIPLINARY COMMUNICATION; LUNG TUBERCULOSIS; MALARIA; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT REFERRAL; PNEUMOCYSTIS PNEUMONIA; POINT OF CARE TESTING; REVIEW; RISK REDUCTION; THERAPY DELAY; TOXOPLASMOSIS; TUBERCULOSIS;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS SERODIAGNOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CONFIDENTIALITY; DIRECTIVE COUNSELING; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; PATIENT COMPLIANCE; TIME FACTORS;

EID: 83455233895     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.151     Document Type: Review

References (82)

1. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367(9513), 817-824 (2006).
2. Nakanjako D, Colebunders R, Coutinho AG, Kamya MR. Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev. 11(4), 179-189 (2009).
3. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr. Opin. HIV AIDS 5(1), 18-26 (2010).
4. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 8(7), e1001056 (2011).
5. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst. Rev. 3, CD008272 (2010).
6. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immu. Defic. Syndr. 46(4), 456-462 (2007).
7. Leisegang R, Cleary S, Hislop M, et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med. 6(12), e1000189 (2009).
8. Boothroyd J. World Health Organization. Dept. of HIV/AIDS. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. World Health Organization, Geneva, Switzerland (2008).
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. World Health Organization, Geneva, Switzerland (2010).
10. Myatt C, Givens M, Ives J, et al. Low-cost imaging cytometer for point-of-care CD4+ cell counting. Low-cost imaging cytometer for point-of-care CD4+ cell counting. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
11. Henkel T, Gohde R, Ost V, Gohde W. True point-of-care CD4/CD4% testing with highest accuracy and precision. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
12. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J. Acquir. Immu. Defic. Syndr. 58(2), 141-147 (2011).
13. Faal M, Naidoo N, Glencross DK, Venter WD, Osih R. Providing immediate CD4 count results at HIV testing improves ART initiation. J. Acquir. Immu. Defic. Syndr. 58(3), e54-e59 (2011).
14. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO Stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans. R. Soc. Trop. Med. Hyg. 104(5), 313-319 (2010).
15. Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One 6(5), e19201 (2011).
16. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immu. Defic. Syndr. 56(3), e79-e86 (2011).
17. Kohler PK, Chung MH, Mcgrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC. Implementation of free cotrimoxazole prophylaxis improves clinic retention among ART-ineligible clients in Kenya. AIDS 25(13), 1657-1661 (2011).
18. Togun T, Peterson I, Jaffar S, et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res. Ther. 8(1), 24 (2011).
19. Lubega M. Lost in transition: pre-antiretroviral care and delayed initiation of antiretroviral therapy in Uganda. Thesis. Co-published by Makere University (Kampala, Uganda) and the Karolinska Institutet (Stockholm, Sweden), May 11 2011.
20. Mcguire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop. Med. Int. Health 15(Suppl. 1), 55-62 (2010).
21. Nilsson Schonnesson L, Ross MW, Bergbrant IM. Coping modes with HIV disease predict loss from HIV study cohort. Int. J. STD AIDS 16(7), 479-481 (2005).
22. Mahendra VS, Gilborn L, Bharat S, et al. Understanding and measuring AIDS-related stigma in health care settings: a developing country perspective. Sahara J. 4(2), 616-625 (2007).
23. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull. World Health Organ. 86(7), 559-567 (2008).
24. Zachariah R, Ford N, Philips M, et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. 103(6), 549-558 (2009).
25. Nash DWY, Elul B, Hoos D, El Sadr W. For the international center for aids care and treatment programs (Icap). Program-and contextual-level determinants of low median CD4+ cell count in cohorts of persons initiating ART in 8 sub-Saharan African countries. AIDS 25(12), 1523-1533 (2011).
26. Tweya H, Gareta D, Chagwera F, et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the Back-to-Care project in Lilongwe, Malawi. Trop. Med. Int. Health 15(Suppl. 1), S82-S89 (2010).
27. Thomson KA, Cheti EO, Reid T. Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya. Trans. R. Soc. Trop. Med. Hyg. 105(6), 320-326 (2011).
28. Do NT, Phiri K, Bussmann H, Gaolathe T, Marlink RG, Wester CW. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res. Hum. Retrovir. 26(6), 685-691 (2010).
29. Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias nduced by missing data. J. Antimicrob. Chemother. 64(3), 599-606 (2009).
30. Peterson I, Togun O, de Silva T, et al. Mortality and immuno-virological outcomes on antiretroviral therapy in HIV-1 and HIV-2 infected individuals in the Gambia, West Africa. AIDS 25(17), 2167-2175 (2011).
31. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med . 6(1), e11 (2009).
32. Obermeyer CM, Baijal P, Pegurri E. Facilitating HIV disclosure across diverse settings: a review. Am. J. Pub. Health 101(6), 1011-1023 (2011).
33. Landon BE, Wilson IB, Mcinnes K, et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch. Intern. Med. 165(10), 1133-1139 (2005).
34. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One 5(9), e12888 (2010).
35. Apaka C. Correlates of missed visits by participants enrolled in an HIV prevention clinical trial in Eldoret, Kenya. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
36. Brennan A, Long L, Maskew M, et al. Outcomes of stable HIV-positive patients down-referred from doctor-managed antiretroviral therapy clinics to nurse-managed primary health clinics for monitoring and treatment. AIDS 25(16), 2027-2036 (2011).
37. Cooke GS, Tanser FC, Barnighausen TW, Newell ML. Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Pub. Health 10, 585 (2010).
38. Massaquoi M, Zachariah R, Manzi M, et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans. R. Soc. Trop. Med. Hyg. 103(6), 594-600 (2009).
39. Gardner EM, Mclees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin. Infect. Dis. 52(6), 793-800 (2011).
40. Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav. 15(4), 751-760 (2011).
41. Van Rie A, Sabue M, Jarrett N, et al. Counseling and testing TB patients for HIV: evaluation of three implementation models in Kinshasa, Congo. Int. J. Tuberc. Lung Dis. 12(3 Suppl. 1), S73-S78 (2008).
42. Marcellin F, Abe C, Loubiere S, et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS 23(8), 1015-1019 (2009).
43. Elbireer S, Guwatudde D, Mudiope P, Nabbuye-Sekandi J, Manabe YC. Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda. Trop. Med. Int. Health doi:10.1111/j.1365-3156.2011.02800.x. (2011) (Epub ahead of print).
44. World Health Organization. Stop TB Dept., UNAIDS, PEPFAR. A guide to monitoring and evaluation for collaborative TB/HIV activities. World Health Organization, Geneva, Switzerland (2009).
45. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22(15), 1897-1908 (2008).
46. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev. 12(4), 183-194 (2010).
47. Reynolds S, Makumbi F, Kiwanuka N, et al. Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo-controlled trial in Rakai, Uganda. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
48. Ludema C, Cole SR, Poole C, Chu H, Eron JJ. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 25(10), 1265-1269 (2011).
49. Cain KP, Mccarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med. 362(8), 707-716 (2010).
50. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 8(1), e1000391 (2011).
51. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. World Health Organization, Geneva, Switzerland (2011).
52. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational How-to; practical considerations. World Health Organization, Geneva, Switzerland (2011).
53. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377(9776), 1495-1505 (2011).
54. Wilson D, Mbhele L, Badri M, et al. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int. J. Tuberc. Lung Dis. 15(7), 919-924 (2011).
55. Havlir D, Ive P, Kendall M, et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE Study. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 27-March 2 2011.
56. Karim SA, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT Trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 27-March 2 2011.
57. Franke MF, Robins JM, Mugabo J, et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med. 8(5), e1001029 (2011).
58. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 52(11), 1374-1383 (2011).
59. Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin. Infect. Dis. 52(11), 1384-1387 (2011).
60. Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J. Acquir. Immu. Defic. Syndr. 58(1), 32-37 (2011).
61. World Health Organization. Stop TB Dept., World Health Organization. Dept. of HIV/AIDS. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva, Switzerland (2011).
62. Fenner L, Forster M, Boulle A, et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int. J. Tuberc. Lung Dis. 15(5), 620-627 (2011).
63. Smith BM, Menzies D. Treatment of latent TB: first do no harm. Expert Rev. Anti. Infect. Ther. 9(5), 491-493 (2011).
64. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochr. Datab. Syst. Rev. 1, CD000171 (2010).
65. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 50(3), 291-322 (2010).
66. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin. Infect. Dis. 51(4), 448-455 (2010).
67. Kendi C, Penner J, Otieno B, et al. Routine cryptococcal screening and treatment in Kenya: outcomes after six months of follow-up. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
68. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
69. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis. 53(4), 321-325 (2011).
70. Lin TY, Yeh KM, Lin JC, Wang NC, Peng MY, Chang FY. Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers. J. Microbiol. Immunol. Infect. 42(3), 220-226 (2009).
71. Kisenge PR, Hawkins AT, Maro VP, et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect. Dis. 7, 39 (2007).
72. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin. Infect. Dis. 50(11), 1532-1538 (2010).
73. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45(1), 76-80 (2007).
74. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 50(3), 338-344 (2010).
75. Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 24(11), 1709-1716 (2010).
76. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375(9722), 1278-1286 (2010).
77. Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst. Rev. 2, CD005646 (2007).
78. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 8(3), e1000422 (2011).
79. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst. Rev. 3, CD001442 (2006).
80. UNAIDS. 2010 Global Report. Annex 1: HIV and AIDS estimates and data, 2009 and 2001 (2010). www.unaids.org/documents/20101123- GlobalReport-Annexes1- em.pdf (Accessed 24 June 2011)
81. Khayelitsha 2001-2011: 10 years of HIV/TB care at a primary health care level (2011). www.msf.org.za/publication/khayelitsha-activity-report-2001-2011- 10-years-hivtb-care-primary-health-care-level (Accessed 26 June 2011)
82. PROMPT Trial. http://prompt-trial.net (Accessed 21 June 2011)